FIELD: medicine.
SUBSTANCE: group of inventions relates to a long-term degradable subcutaneous implant with a prolonged release of a pre-concentrated pharmaceutically active substance in a polymer for the treatment of chronic adrenal insufficiency or hypocortisolism, which is characterized by the fact that the biodegradable hydrocortisone implant remains in the polymer matrix, while the biodegradable implant contains from 5 mg to 250 mg of hydrocortisone uniformly distributed in said bioabsorbable polymer matrix, wherein composition of polymer matrix is from 1% to 20% of biodegradable polymer with respect to weight of hydrocortisone, and also relates to a long-term degradable subcutaneous implant with a pre-concentrated pharmaceutically active substance in a polymer for the treatment of chronic adrenal insufficiency or hypocortisolism, which is characterized by that the implant is presented in a non-biodegradable or non-biodegradable form (2), having central core (2.1) formed by a polymer matrix in a percentage ratio of 1% to 20% with respect to the weight of the drug, in this case, from 5 mg to 250 mg of hydrocortisone, the nucleus is surrounded by a non-degradable polymer membrane (2.2).
EFFECT: group of inventions provides reducing inflammation and pain, as well as restoring the patient’s circadian cycle in order to restore the physiology of life-wakefulness during the day and sleep at night.
8 cl, 4 dwg
